Can the Tuberculosis Vaccine Reduce the COVID-19 Death Rates?

Can the Tuberculosis Vaccine Reduce the COVID-19 Death Rates

Can a vaccine that was developed to stop tuberculosis actually inhibit or stop SARS-CoV-2, the virus behind COVID-19?  With evidence that the Bacille Calmette-Guérin (“BCG”) vaccine can protect against other viral infections, dozens of studies around the world are investigating this very vaccine as a defense against COVID-19. For example, the UK’s University of Exeter will test this hypothesis on about 1,000 clinical trial volunteers. This UK study is part of the international Brace-study, involving Australia, the Netherlands, Spain and Brazil and involving 10,000 people. TrialSite also reminds us that in the U.S., Texas A&M has a prominent study investigating whether the BCG vaccine can inhibit or stop COVID-19.

James Gallagher of the BBC recently reported on this interesting topic. As vaccines are developed to boost the body’s immune defense against targeted pathogens, as they impact and trigger significant changes in the immune system writes Gallagher, this very well could “heighten the response to other infections and scientists hope it may even give our bodies an advantage against coronavirus.” Back in July, TrialSite reported that there were at least 17 clinical trial...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee